Corporation, a clinical-stage cancer pharmaceutical company founded by
world-renowned oncologists, has a lead compound, Amplimexon®, in Phase II
clinical trials, with early evidence of effectiveness and low levels of
toxicity. Disease targets include pancreatic cancer, lung cancer and
melanoma. The Company also has three promising drug classes in pre-clinical
development, cyanoaziridines, azonafides and benzimidazole analogs. The
Company is focused on the development of small-molecule oncology drugs with
novel mechanisms of action. The major effort of the Company is to bring its
drugs through Phase I-III clinical trials as quickly, efficiently and as
cost effectively as possible. AmpliMed Corp..
*Cialis générique - la France pharmacie.